Navigation Links
Cordex Completes Production of ATPace(TM) Clinical Trial Material
Date:6/29/2009

LA JOLLA, Calif., June 29 /PRNewswire-FirstCall/ -- Cordex Pharma, Inc. (OTC Bulletin Board: CDXP) announced today that it has successfully completed the production of the ATPace(TM) clinical trial material (CTM) in preparation for planned pivotal clinical trials. The protocol of these clinical trials has been approved by the U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment process.

ATPace(TM) is a novel, proprietary, stable, injectable formulation of adenosine 5'-triphosphate (ATP) under development as a therapeutic and diagnostic drug for the management of cardiac arrhythmias. A stable liquid formulation of ATP is a prerequisite for ATPace(TM)'s clinical superiority over adenosine, the only approved competition in the U.S. The maintenance of intact ATP molecules in solution is critical for the unique bradycardic effects of ATP, in particular its blockade of atrio-ventricular nodal conduction. Cordex has filed a formulation patent covering this stable liquid formulation of ATP for intravenous administration.

The ATPace(TM) CTM was produced off-site by a U.S. manufacturer of sterile injectable products under the regulatory supervision of Cordex and Cato Research, Inc. The CTM will be used in the planned clinical trials for the acute treatment of patients presenting with paroxysmal supraventricular tachycardia (PSVT) in the emergency room.

Several formulations of ATP have been used in Europe for over five decades as the drug of choice for the acute conversion of PSVT to normal sinus rhythm. During this extended period of use, ATP manifested an excellent safety and efficacy profile. Cordex intends to use clinical data obtained in Europe as a part of the ATPace(TM)'s NDA under section 505b(2).

"We are pleased to reach this important milestone in the development program of ATPace(TM)," said Amir Pelleg, Ph.D., Cordex's President and CSO. "Together with Cato Research,
'/>"/>

SOURCE Cordex Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Cordex Pharma Forms Heart Failure Medical Advisory Board
2. Cordex Pharma Presents New Frontiers in Cardiovascular Medicines on January 29
3. OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer
4. Brooks Instrument Completes Acquisition of Celerity's Instrumentation Division
5. Sinovac Completes Construction of H1N1 Virus Seed Bank
6. Medivation Completes Enrollment in Confirmatory, Pivotal Phase 3 CONNECTION Trial of Dimebon in Patients With Alzheimers Disease
7. Proteon Therapeutics Completes Second Closing of Equity Financing; Raises Total Series B to $50 million
8. Charleston Laboratories, Inc. Completes Exploratory Bioequivalence Study of CL-108
9. Clarient Completes Second Tranche of Private Placement of Convertible Preferred Stock With Oak Investment Partners
10. Oncolytics(R) Biotech Inc. Completes Patient Enrolment in U.S. Phase 2 Sarcoma Study
11. NovImmune Completes CHF 62.5 (USD 54.8) Million Equity Financing to Move Portfolio Forward and Reacquire Product Rights to Lead Antibodies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... 21, 2015  This research service analyzes the various ... and biotechnology industry. The deals are analyzed based on ... based on the geographic region and buyer types. The ... takes into account various deal multiples such as enterprise ... target company. Executive Summary ...
(Date:4/21/2015)... Texas , April 21, 2015 ... grow from $313.0 million in 2014 to $605.1 million by ... under consideration. Browse through the TOC of ... an in-depth analysis of the industry trends and segments, ... http://www.micromarketmonitor.com/market/north-america-bio-stimulants-6850160039.html Early buyers will ...
(Date:4/21/2015)... 2015 AbilTo, Inc., the nation,s leading digital ... has been accepted as a presentation to be included ... place on June 5-6, 2015 in Boston, Massachusetts ... Diabetes Association, the cost of diabetes to the American ... result of increased inpatient, outpatient, and pharmacy costs, the ...
(Date:4/21/2015)... YORK , April 21, 2015 Immune ... that its Board of Directors has elected Rene-Pierre ... the Transaction and Pricing Committee, with oversight on strategic ... member of the Audit Committee, the Compensation Committee and ... his election, Mr. Azria commented: "I have a long-time ...
Breaking Biology Technology:Funding Patterns in the Global Pharma and Biotech Industry 2North America Biostimulants Market is Expected to Reach $605.1 Million by 2019, at a CAGR of 14.1% From 2014 to 2019 2North America Biostimulants Market is Expected to Reach $605.1 Million by 2019, at a CAGR of 14.1% From 2014 to 2019 3AbilTo To Present at the 2015 American Diabetes Association Annual Meeting on Remote Delivery of Behavioral Change Therapy 2AbilTo To Present at the 2015 American Diabetes Association Annual Meeting on Remote Delivery of Behavioral Change Therapy 3Immune Board Elects Rene-Pierre Azria A Director And Chair Of The Transaction Committee 2Immune Board Elects Rene-Pierre Azria A Director And Chair Of The Transaction Committee 3Immune Board Elects Rene-Pierre Azria A Director And Chair Of The Transaction Committee 4
... 10 /Xinhua-PRNewswire/ -- WuXi PharmaTech (NYSE:,WX), a leading pharmaceutical, ... operations in China and the United,States, today announced that ... Most,Innovative Enterprises" and its CEO Dr. Ge Li was ... Chinese Enterprises" at the 8th China,Enterprise Innovation Forum held ...
... access to 'Best Practices for Long-term Jatropha ... Rajagopal's highly successful November 2007 position paper ... is being offered. It emphasizes the need ... it nears commercialization as a viable alternative ...
... Australia, July 10 Cytopia (ASX: CYT),announced today ... Scientific,Advisor to the company., Based in California, ... executive management team, on a part-time basis during ... has held global,leadership roles at Glaxo Wellcome and ...
Cached Biology Technology:WuXi PharmaTech (NYSE: WX) Named the Most Innovative Company in China and CEO Dr. Li the Most Innovative Leader of Chinese Enterprises 2Comprehensive Jatropha Standards Mandatory in Optimum Long-term Biofuel Efficacy 2Comprehensive Jatropha Standards Mandatory in Optimum Long-term Biofuel Efficacy 3Comprehensive Jatropha Standards Mandatory in Optimum Long-term Biofuel Efficacy 4Cytopia Strengthens Scientific Team With US-Based Drug Development Specialist 2
(Date:3/20/2015)... Mar. 20, 2015 Research and Markets ... of the "India Sensors Market Forecast and ... The sensor market is projected to grow ... Consumer electronics, automotive, industrial and healthcare sectors ... the country. In addition, adoption of MEMS technology ...
(Date:3/20/2015)... , March 20, 2015 NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... wallet is one of the products featured in 2015 ... 20th at 11:00 PM EST on the DIY Network. ... Las Vegas , site of the ...
(Date:3/19/2015)...  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... mobile commerce market, announces its biometric payment technology, the Wocket® ... this week on Washington DC,s Fox ... segment "The Next Great Thing", host Laura Evans ... and ,a really big breakthrough in mobile payment.,  ...
Breaking Biology News(10 mins):India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3
... 2010) -- A cell devotes a significant amount of ... sorts of chromosomal rearrangements characteristic of many cancers. Assays ... needed in order to understand the individual genes and the ... issue of Cold Spring Harbor Protocols , ...
... developed by Laszlo Otvos, a research professor of ... looks to be a highly-effective therapy against infections ... Otvos and his collaborators found that when ... than current antimicrobial chemotherapy measures in treating multidrug-resistant ...
... Park, MD (August 31, 2010) -- A new imaging ... of the eyeball (ocular fundus) may pave the way ... of the eye, such as age-related macular degeneration and ... Review of Scientific Instruments, which is published ...
Cached Biology News:Cold Spring Harbor Protocols features chromosomal rearrangement, gene copy number methods 2LEDs illuminate eye for ocular disease screening 2
... This antibody is specific for human cardiac troponin ... the Ca-binding signals responsible for contraction of cardiac ... troponin complex in human cells. It also cross-reacts ... Antigen: Highly purified human ...
...
Troponin I Immunogen: Full length native protein (purified) (Human). Storage: -20 C, Avoid Freeze/Thaw Cycles...
Anti-SDF-1β/PBSF affinity isolated antibody lyophilized powder Lyophilized from a 0.2 μm filtered solution in phosphate buffered saline recombinant human SDF-1β/PBSF expressed in E....
Biology Products: